PARTNER randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.
Authors
Abraham, JVallier, A
Qian, W
Grybowicz, L
Thomas, S
Machin, A
Harvey, C
Chiu, E
McAdam, K
Hughes-Davies, L
Roylance, R
Copson, E
Armstrong, Anne C
Provenzano, E
Tischkowitz, M
McMurtry, E
Earl, H
Affiliation
University of Cambridge, CambridgeIssue Date
2018-02-14
Metadata
Show full item recordCitation
PARTNER randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients 2018, 78(4 Suppl): OT3-04-03 Cancer ResJournal
Cancer ResearchDOI
10.1158/1538-7445.SABCS17-OT3-04-03Type
Meetings and ProceedingsLanguage
enISSN
0008-54721538-7445
ae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.SABCS17-OT3-04-03